PORTFOLIO NEWSLETTER

JANUARY 2021

NIHR University College London Hospital Clinical Research Facility Cancer Trials

INSIDE THIS ISSUE:

COVID-19 and Early Phase Cancer Trials at UCLH

During this difficult time we are trying to keep the early phase cancer trials program open to enrolment. The CRF is a geographically distinct unit to the main hospital and patients are treated in individual rooms as much as possible to minimize infection risk.

We therefore continue to welcome referrals; however due to the pressures at the front line, we are running at limited capacity and may not be able to take your patient immediately. Please liaise with the PI of the study you are considering referring to.

This newsletter provides you with details of the current ongoing cancer trials.

Dr. Rakesh Popat, Consultant Haematologist

Cancer Lead NIHR UCLH Clinical Research Facility

Spotlight on Research

Senior Clinical Lecturer & Consultant Medical Oncologist

This month we will highlight research conducted by Dr. Sandra Strauss.
Dr. Strauss is a Senior Clinical Lecturer & Consultant Medical Oncologist. She specialises in the systemic management of bone and soft tissue sarcomas in teenage Young adult (TYA) and adults patients. There are over 100 subtypes of sarcomas many of which don't have a standard of care.
Sandra has an appointment at UCL that aims to improve access of sarcoma patients of all ages to early phase and novel therapies - *https://iris.ucl.ac.uk/iris/browse/profile?upi=SSTRA61*

ESP1/SARC025

The 'ESPIRIT' trial was an academic global phase I study, sponsored by SARC, investigating the tolerance & efficacy of a PARP1/2 inhibitor Niraparib in combination with temozolomide or Irinotecan in patients with recurrent Ewing sarcoma. Dr. Strauss was Co-Chief Investigator of the study.
The trial recruited internationally, with UCLH being the only site open In Europe and first study within the CRF to recruit TYA patients. The study is now closed to accrual at all participating sites.
We are pleased to share recently published results of the clinical trial. Translational biomarker analysis is on-going.

Chugh, R, Ballman, KV, Helman, LJ, Patel, S, Whelan, JS, Widemann, B, Lu, Y, Hawkins, DS, Mascarenhas, L, Glod, JW, Ji, J, Zhang, Y, Reinke, D, ***Strauss, SJ****. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer. 2020. https://doi.org/10.1002/cncr.33349*

Afatinib in Chordoma

Chordoma is a rare bone tumour, usually occurring at the base of the skull or the pelvis, with an incidence of approx. 0.8/1,000,000 with no licenced systemic treatment options. This study is investigating the role of the EGFR inhibitor, Afatinib in first-line or later-line treatment in locally advanced and metastatic Chordoma. It's an academic trial developed in part on the basis of preclinical studies led by UCL's Prof. Adrienne Flanagan. The trial is an international academic partnership developed between Leiden University, UCL, and The Istituto Tumori, Milan and funded by Leiden University Medical Center, Chordoma Foundation and Boehringer Ingelheim. The study opened in March 2019 *(UCLH BRC featured news item)* and to date UCLH has recruited 10 patients. Based on preliminary efficacy demonstrated within the first cohort of patients, recruitment has been extended of the trial.
For further details & eligibility see UCLH Find a Study, reference 17/0146.

ImmunoSARC-2

We are excited to announce we are in set-up for an innovative phase I/II study of Sunitinib and Nivolumab in patients with 6 rare subtypes of soft tissue and bone Sarcomas, including Conventional and Dedifferentiated Chondrosarcoma, Extraskeletal Myxoid Chondrosarcoma, Vascular Sarcomas, Solitary Fibrous Tumour, Alveolar Soft Part Sarcoma and Clear Cell Sarcoma, many of which have no defined treatments. Importantly it is open to Teenage/Young Adult patients.
This is an academic collaboration sponsored by the Spanish Group for Research on Sarcoma (GEIS) with sites in Spain, Italy and ULCH as the only site in the UK. We are very grateful to the Jon Moulton Trust for their financial support to conduct the study at UCLH, and we are delighted that Fatjon Dekaj has joined as study co-ordinator.
For further details on the study please see ClinicalTrials.Gov, reference NCT03277924.

Latest News

New Staff Member

We would like to welcome Fatjon Dekaj as our new Early Phase Cancer Trials Research Manager.

Fatjon will be overseeing our communications as well as building new webpages for the cancer program.
He will have a role in developing PPI/E within the cancer trials program and will manage the portfolio oversight. He will also have a role on the Sarcoma trials conducted by Dr. Sandra Strauss.
Fatjon is keen to develop the webpages with clinicians and the public/patients in mind.

How to refer a patient

By Post:
NIHR UCLH Clinical Research Facility,
University College London Hospitals NHS Foundation Trust, 4th Floor, 170 Tottenham Court Road,
London, W1T 7HA

By Telephone:
Reception: 020344 72929/72930
Reception Fax: 020344 72994

By Email*:
*When referring patients, ensure you use nhs.net emails. Patient identifiable data *should not* be sent to/via non-NHS email accounts.

Principal Investigator

Prof. John Bridgewater

Dr. Martin Forster

Prof. Daniel Hochhauser

Prof. Sam Janes

Dr. Mark Linch

Prof. Tim Meyer

Dr. Rowan Miller

Dr. Jenny O'Nions

Dr. Dionysis Papadatos-Pastos

Dr. Rakesh Popat

Dr. Rebecca Roylance

Dr. Beatrice Seddon

Dr. Heather Shaw

Dr. Sandra Strauss

Dr. William Townsend

Contents

As it appears in alphabetical order

UCLH Find a Study

To find more information on UCLH CRF Early Phase Cancer Clinical Trials visit the UCLH Find a Study database:

https://findastudy.uclh.nhs.uk/#/trial

Using the 'Study Name' and/or 'Local Project Reference' (LRP).

NIHR UCLH Clinical Research Facility
Cancer Trials Open to Recruitment

For more information on a trial, including eligibility criteria click the hyperlinked **Local Project Reference (LRP)** ID.

Breast

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
B-PRECISE-01 (MEN1611-01) Open-label, Multicentre, Phase Ib Dose-escalation Study of MENI6I 1, a P13K Inhibitor Combined with Trastuzumab ± Fulvestrant, in Subjects with PIK3CA Mutated HER2-positive Locally Recurrent Unresectable (advanced) or Metastatic Breast Cancer Progressed to Anti-HER2 Based Therapy.	120910	Dr. Rebecca Roylance	**P13K Inhibitor** PIK3CA Mutated HER2-positive Locally Recurrent Unresectable (advanced) or Metastatic Breast Cancer.

Gynaecological

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
GCT1015-05 ENGOT innovaTV 205: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer.	113569	Dr. Rowan Miller	**Antibody-Drug Conjugate (ADC) Targeting Tissue Factor (TF).** Recurrent or Stage IVB Cervical Cancer.

Haematology

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
ASTX660 Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas.	106548	Dr. William Townsend	**Dual Antagonist of Cellular Inhibitor of Apoptosis cIAP & XIAP** Relapsed T-Cell Lymphomas
BP41072 An Open-Label, Phase I Study To Evaluate The Safety, Pharmacokinetics And Preliminary Antitumor Activity Of Ro7227166 (A Cd19 Targeted 4-1bb Ligand) In Combination With Obinutuzumab And Incombination With Ro7082859 (Cd20-Tcb) Following A Pre-Treatment Dose Of Obinutuzumab Administered In Participants With Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma.	129333	Dr. William Townsend	**Ro7227166 (CD19-directed 41BB ligand) + Obinutuzumab (anti-CD20 Monoclonal Antibody) or Glofitamab (CD3-CD20 T-Cell Bispecific Antibody)** Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
DREAMM-6 A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment Arm A), or Bortezomib Plus Dexamethasone (Treatment Arm B) in Participants with Relapsed or Refractory Multiple Myeloma.	18/0571	Dr. Rakesh Popat	**Humanised Monoclonal Antibody (anti-BCMA)** Relapsed or Refractory Multiple Myeloma.

Haematology (II)

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
Teclistamab in Relapsed or Refractory Multiple Myeloma A Phase 1/2b, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanised BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma.	134949	Dr. Rakesh Popat	**Humanised Bispecific Antibody (BCMA & CD3)** Relapsed or Refractory Multiple Myeloma.

Hepatobiliary

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
ADP-0033-001 A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein ($AFP^{c332}T$) in HLA -A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types.	17/0093	Prof. Tim Meyer	**T-Cell Therapy** Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumour Types.

Lung

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
TACTICAL Targeted Stromal Cells Expressing TRAIL as a therapy for lung cancer.	14/0453	Prof. Sam Janes	**MSC-TRAIL with chemo-immunotherapy as first line therapy** Advanced Lung Cancer

Sarcoma

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
Afatinib in Chordoma A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first-line or later-line treatment in advanced Chordoma.	17/0146	Dr. Sandra Strauss	**EGFR Small Molecule Inhibitor.** Advanced Chordoma
DCC-3014 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors.	128373	Dr. Beatrice Seddon	**Tyrosine Kinase Inhibitor.** Cohort B only (Expansion Phase) — Tenosynovial Giant Cell Tumour (DTGCT).

Solid Tumours

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
AGI-134 A phase I/IIa, multicentre, open label study designed to evaluate the safety and tolerability of AGI-134 as monotherapy and in combination with pembrolizumab, in unresectable metastatic solid tumours.	104916	Dr. Martin Forster	**Anti-αGal** Unresectable superficial metastatic melanoma or Squamous Cell Cancers.
BLU-667 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors.	17/0783	Dr. Martin Forster	**RET Inhibitor** Thyroid Cancer, NSCLC, Other RET-driven Advanced Solid Tumours.
Cancer Peptide Vaccine Open-label, phase 1 study of S-488210/S-488211 to evaluate the safety and tolerability in patients with unresectable recurrent and/or metastatic solid tumor.	119614	Dr. Mark Linch	**5-peptide cancer vaccine** Unresectable recurrent and/or metastatic solid tumour.
FIGHT-207 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations.	124183	Prof. John Bridgewater	**FGFR Inhibitor** Advanced/Metastatic or Surgically Unrespectable Solid Tumour Malignancies Harbouring Activating FGFR Mutations or Translocations.
Garnet A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.	16/0355	Dr. Rowan Miller	**Anti PD-L1 Monoclonal Antibody** Cohorts Open: *Part 2B: Cohort A1* dMMR/MSI-H endometrial cancer. *Part 2B: Cohort F* non-endometrial dMMR/MSI-H & POLE-Mut cancers.
LOXO-TRK-15002 (Navigate) LOXO-TRK-15002: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors.	16/0077	Dr. Martin Forster	**TRK Inhibitor** NTRK Fusion-Positive Tumours.
MOv18 A Cancer Research UK Phase I study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours.	17/0121	Dr. Rowan Miller	**IgE Antibody against Folate Receptor-α** Advanced solid tumours
Starpharma CTX A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours.	18/0016	Dr. Martin Forster	**Drug-Dendrimer Conjugate** Advanced solid tumours

Solid Tumours (II)

Study Acronym/ Full Title	LRP	PI	Drug Class/ Target
Starpharma DTX A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC).	17/0585	Dr. Martin Forster	**Drug-Dendrimer Conjugate (Tubulin Polymerase Inhibitor)** Advanced solid tumours Or non-small cell lung cancer (NSCLC).
TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist).	18/0560	Dr. Martin Forster	**APC Activator &** **Anti-PD-1 Monoclonal Antibody** Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), Or recurrent PD-X refractory NSCLC Or with recurrent or metastatic squamous head and neck cancer (HNSCC).

Urology

Study Acronym/ Full Title	LRP	PI	Drug Class/ Target
BXCL701 A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1(PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC).	113103	Dr. Mark Linch	**Dipeptidyl Peptidases (DPP) Inhibit &** **Anti-PD-1 Monoclonal Antibody** Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)
CORT125281 Phase 1/2 Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.	18/0135	Dr. Mark Linch	**Glucocorticoid Receptor (GR) Antagonist** Metastatic Castration-Resistant Prostate Cancer
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy): A first-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 in patients with metastatic castration resistant prostate cancer and W_pro1 in combination with cemiplimab and/or goserelin acetate in patients with high-risk, localized prostate cancer.	122815	Dr. Mark Linch	**W_pro1 mRNA Cancer Vaccine** *Group 1:* mCRPC that have exhausted conventional treatment. *Group 2:* High-risk, Localized Prostate Cancer prior to Prostatectomy.